Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

sion (abstract #3594) during the American Association for Cancer Research's 100th Annual Meeting 2009 at the Colorado Convention Center in Denver.

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously to patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200 mg, 300 mg or 400 mg). Four weeks later, they received a second single picoplatin dose administered via the other route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 mg and 100 mg).

Final results showed that oral picoplatin achieved oral bioavailability of nearly 100 percent at doses of 50 mg and 100 mg. No meaningful differences in pharmacokinetics were observed between the two formulations. All doses of the oral dose were well tolerated. No serious adverse events related to treatment were noted following administration of the oral dose.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other pl
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel Film ... FCPX filmmakers . , “Fun, cool, and simple are ... Says Christina Austin, CEO of Pixel Film Studios. “It has ... comes with all the tools needed for a full ... added style, a title screen for an introduction, two lower ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... Latest Projections WASHINGTON , May 12 The ... today highlight the imperative to act immediately to address ... the American Academy of Actuaries . The financial ... during the past year and inaction will only make ...
... 12 Pharmos Corporation (Pink Sheets: PARS) today reported results ... recorded a net loss of $3.7 million, or $0.14 per ... loss of $3.6 million, or $0.14 per share, in the ... at March 31, 2009.The slight increase in net loss for ...
... supposed problems of Social Security based on the Social ... U.S. House Aging Committee Director Bob Weiner. Weiner, who ... under Rep. Claude Pepper and later worked for Reps. ... said, "Everyone forgets that Social Security has already absorbed ...
... AmericansWASHINGTON, May 12 Today the Kronos Longevity ... on top longevity research findings over the last ... , http://www.kronosinstitute.org/publications/reports/sos_2009.cfm Director ... Gleason, Ph.D., Associate Scientist/Geriatric Neuropsychologist from the ...
... Barielle is your Summer Savior for Resolving Hard Cuticles. Barielle,s hand cream ... summer. , ... New York, NY (PRWEB) May 14, 2009 -- Pretty ... to toe with a perfect manicure easy enough to execute at home. ...
... research, better adherence to recommendations needed, study suggests , , ... widely varying policies on organ donation after cardiac death ... the United States, Puerto Rico and Canada about their ... received responses from 105 hospitals, and found that 72 ...
Cached Medicine News:Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:Social Security 'Problems' Are 'Misplaced Scare Tactics' and Media Missing Story of Solvency, Says Former Congressional Aging Committee Chief of Staff Bob Weiner 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 3Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 4Health News:Resolve Hard Cuticles this Summer with Barielle Hand Cream 2Health News:Organ Donation Policies Vary Among Children's Hospitals 2
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... Caring, is a 4-Star Sponsor of Operation Grow4Vets ... with unique products, programs and services to assist them ... Key Facts: , An ever-increasing ... a safe and effective treatment for pain, Post-traumatic Stress ...
(Date:10/19/2014)... Wash. , Oct. 20, 2014 CTI ... that it will report its third quarter 2014 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... N.J., Dec. 23, 2010 Dey Pharma, L.P. today ... Meda, a leading international specialty pharma company headquartered in ... EpiPen® (epinephrine) Auto-Injector in Europe. EpiPen Auto-Injector is used ... can occur quickly, often within a couple of minutes, ...
... Partners announced today that it has updated coverage on ... ) ("the Company") and maintains its twelve month target price ... "DAVANAT®, the Company,s lead product candidate, could potentially enhance the ... , while also reducing the side effect profile of these ...
Cached Medicine Technology:Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 2Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 3Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10 2
... Re-insulation capabilities that extend the life ... that bring them back to life, expertise ... Instrument trademark. Our maintenance capabilities always help ... , Economical and fast, not only do ...
Inquire...
... your camera upon arrival.,Our technician then makes note ... with a thorough customer quote. We respect that ... so well help you prioritize repairs. With customer ... , ISI uses only OEM or widely approved ...
... an ISI technician carefully inspects your ... and all problems, and provides you ... respect that you may be working ... help you prioritize repairs. With customer ...
Medicine Products: